Identification of potential biomarkers of peripheral blood mononuclear cell in hepatocellular carcinoma using bioinformatic analysis

Peng, Jinlin; Wu, Jizhou; Li, Guojian; Wu, Jian‐Lin; Xi, Yu-mei; Li, Xiaoqing; Wang, Lei

doi:10.1097/md.0000000000024172

Cited by 6 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A series of steps are involved in the development of cancer cells which involve changes in growth, cell metabolism, proliferation, and adhesion (22,23). Several studies have provided information about the biomarker of liver cancer (24,25). The fact that REXO4 has been identified as a new biomarker for HCC, could aid in elucidating how alterations in cytokinesis and the immune environment stimulate the development of liver cancer.…”

Section: Discussionmentioning

confidence: 99%

The expression and prognostic value of REXO4 in hepatocellular carcinoma

Chen

Gao

Shen³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Globally, one of the dominant causes of cancer-related mortality is liver cancer. Identification of potent biomarkers for initial stage diagnosis and prognosis is a key factor to ensure efficient therapy and reduce the mortality rate in liver cancer patients. REXO4 has been reported in neuropathic pain and familial isolated pituitary adenoma (FIPA), however, its relationship with liver cancer is still elusive.Methods: In an attempt to scrutinize the expression of REXO4 in liver cancer, the Oncomine, and TCGA databases were analyzed. Real-time PCR was employed to identify the REXO4 mRNA levels in 45 patient tissue samples and western blot was used to detect the REXO4 protein levels in hepatocellular carcinoma (HCC) cells. Evaluation of the prognostic value of REXO4 in liver cancer was made using Univariate and multivariate Cox proportional hazards regression models and Kaplan-Meier plots. Tumor-associated biological processes related to REXO4 were revealed by LinkedOmics. The correlation of REXO4 and immune infiltration was evaluated using the TIMER database.Results: REXO4 is significantly up-regulated in liver cancer in comparison with the nontumor controls.Moreover, poor progression-free survival and overall survival is a frequent outcome related to high expression of REXO4, highlighting it as a risk factor in case of liver cancer. Additionally, the plausible role of REXO4 in tumor-immune interactions was also investigated and it was revealed that the immune infiltration and immune activation of liver cancer might have an association with REXO4.Conclusions: REXO4 has a significant expression in liver cancer and could potentially become a predictor for the prognosis of liver cancers and a biomarker for targeted therapeutic regimens. Significant overexpression of REXO4 in HCC was revealed by the bioinformatics analysis, with REXO4 overexpression being related to a negative outcome in HCC patients, in addition, REXO4 might be associated with the immune infiltration in liver cancer. Such a vital understanding of the functioning of REXO4 may furnish a foundation for new targeted drug therapy as well as a new direction for additional investigation into the underlying mechanisms of REXO4 carcinogenesis in liver cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The expression and prognostic value of REXO4 in hepatocellular carcinoma

Chen

Gao

Shen³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…Particularly, the interest in the fraction of peripheral blood mononuclear cells (PBMC) as a biological material for searching for biomarkers related to different diseases, e.g., obesity has grown in the last years. [16][17][18][19] Apart from their role in immunology, PBMC express a significant proportion, around 80%, of the genes encoded by the human genome and act as "sentinel" cells capable of reflecting gene expression profiles of internal tissues. [20] In fact, we have previously shown that gene expression of selected key lipid metabolism genes in human PBMC is affected by OW-OB in the same way as in crucial energy homeostatic tissues.…”

Section: Introductionmentioning

confidence: 99%

Whole‐Genome Transcriptomics of PBMC to Identify Biomarkers of Early Metabolic Risk in Apparently Healthy People with Overweight‐Obesity and in Normal‐Weight Subjects

Costa

Stelt

Reynés

et al. 2023

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope Peripheral blood mononuclear cells (PBMC) provide a useful and minimally invasive source of biomarkers. Here to identify PBMC transcriptomic biomarkers predictive of metabolic impairment related to increased adiposity is aimed. Methods and results The study analyzed the global PBMC transcriptome in metabolically healthy (normoglycemic) volunteers with overweight‐obesity (OW‐OB, n = 12), and in subjects with metabolically obese normal‐weight (MONW, n = 5) phenotype, in comparison to normal‐weight (NW, n = 12) controls. The study identifies 1072 differentially expressed genes (DEGs) in OW‐OB versus NW and 992 in MONW versus NW. Hierarchical clustering of the top 100 DEGs clearly distinguishes OW‐OB and MONW from NW. Remarkably, the OW‐OB and MONW phenotypes share 257 DEGs regulated in the same direction. The top up‐regulated gene CXCL8, coding for interleukin 8, with a role in obesity‐related pathologies, is of special interest as a potential marker for predicting increased metabolic risk. CXCL8 expression is increased mainly in the MONW group and correlated directly with C‐reactive protein levels. Conclusions PBMC gene expression analysis of CXCL8 or a pool of DEGs may be used to identify early metabolic risk in an apparently healthy population regardless of their BMI, i.e., subjects with OW‐OB or MONW phenotype and to apply adequate and personalized nutritional preventive strategies.

show abstract

“…Despite a decrease in the mortality rate of patients diagnosed in the early stages of the disease's progression, the overall survival (OS) for advancedstage liver cancer patients can still be improved (2). Patients are frequently identified with advanced-stage liver cancer and are unable to obtain appropriate therapy because of a lack of highly specific and specific early diagnostic biomarkers, and thus their prognosis is poor (3). It is critical to investigate new HCC markers to enhance the prognosis of HCC patients, as well as to better understand the molecular pathways driving carcinogenesis and cancer progression.…”

Section: Introductionmentioning

confidence: 99%

Increased RBM12 expression predicts poor prognosis in hepatocellular carcinoma based on bioinformatics

Gao¹,

Shen²,

Chen³

et al. 2021

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Liver cancer is one of the major causes of cancer death worldwide, incurring high mortality and a significant financial burden on the healthcare system. Abnormal RNA-binding proteins (RBPs) have been found to be associated with carcinogenesis in liver cancer. Among these, RNA-binding motif protein 12 (RBM12) is located in the exon junction complex (EJC). The goal of this study was to determine what role RBM12 plays in hepatocellular carcinoma (HCC) from a biological perspective. Methods:The Tumor IMmune Estimation Resource (TIMER) and the Human Protein Atlas database were used to examine the expression level of RBM12, with the UALCAN and Gene Expression Profiling Interactive Analysis (GEPIA) databases used to investigate the relationship between RBM12 and other noteworthy clinical features. RBM12 expression in cells and tissue samples was detected using quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analysis. The functional network of RBM12 in HCC was studied using LinkedOmics and gene set enrichment analysis (GSEA), while the effects of hypomethylation on the expression of RBM12 in HCC was investigated using methylation databases. Finally, we used TIMER and CIBERSORT to investigate the relationship between immune cell infiltration and RBM12 in HCC.Results: RBM12 is highly elevated in HCC tissues and cells, and it can be used to predict the prognosis of patients with HCC. Analysis with LinkedOmics and GSEA revealed RBM12 to be closely linked with tumor progression. Furthermore, hypomethylation was linked to an increase in RBM12 expression in HCC, while RBM12 was associated with immune cell infiltration.Conclusions: This study shows that an elevated level of RBM12 in HCC indicates a poor patient prognosis. Furthermore, according to LinkedOmics and GSEA analyses, RBM12 was implicated in the most important hallmark pathways. Our findings suggest that RBM12 overexpression is caused by hypomethylation and that RBM12 plays a key role in liver cancer tumor immunity.

show abstract

Identification of potential biomarkers of peripheral blood mononuclear cell in hepatocellular carcinoma using bioinformatic analysis

Cited by 6 publications

References 50 publications

The expression and prognostic value of REXO4 in hepatocellular carcinoma

The expression and prognostic value of REXO4 in hepatocellular carcinoma

Whole‐Genome Transcriptomics of PBMC to Identify Biomarkers of Early Metabolic Risk in Apparently Healthy People with Overweight‐Obesity and in Normal‐Weight Subjects

Increased RBM12 expression predicts poor prognosis in hepatocellular carcinoma based on bioinformatics

Contact Info

Product

Resources

About